What is Gilead Sciences' current financial performance like in terms of revenue and profitability?

In the second quarter of 2001, Gilead Sciences reported total revenues of $50.7 million, a slight increase from $50.1 million in the prior year. For the first six months of 2001, revenues were $108.5 million, up from $97.8 million in the same period of 2000. However, the company continued to experience significant net losses. The net loss for the second quarter was $32.4 million, and for the first six months, it was $54.1 million, a notable increase from the losses reported in the corresponding periods of 2000.

What are the main drivers of Gilead's revenue growth and expenses?

Revenue growth is primarily driven by product sales, particularly AmBisome®, which saw a 9% increase in the second quarter and a 17% increase in the first six months of 2001. However, foreign currency fluctuations have impacted the reported U.S. dollar value of these sales. On the expense side, Research and Development (R&D) is a major focus, with a significant increase of 61% in Q2 and 77% in the first six months of 2001. This spending is concentrated on late-stage clinical trials for key pipeline drugs like Viread™ and adefovir dipivoxil, in preparation for future commercial launches.

What is the company's cash position and liquidity outlook?

Gilead Sciences' cash and cash equivalents decreased substantially by $150.4 million during the first six months of 2001, ending the period on June 30, 2001, with $46.9 million. This decrease was primarily due to cash used in operating and investing activities, including significant R&D investments. The company believes its existing capital resources, along with expected revenues, will be adequate for its foreseeable needs, but acknowledges the potential need for future funding.

What are the key risks and challenges facing Gilead Sciences as highlighted in this filing?

Key risks include reliance on AmBisome® sales, the lengthy and expensive regulatory approval process, market acceptance of new products, potential failures in collaborations with partners (like Roche and Fujisawa), foreign currency fluctuations impacting revenues and margins, and the general uncertainty of financial results given the company has historically not been profitable. The substantial accumulated deficit of $560.1 million as of June 30, 2001, underscores the company's ongoing need to secure funding and achieve profitability.

GILD 10-Q Quarterly Report Q2 FY2001 — Revenue, Net Income, EPS

Summary

Gilead Sciences, Inc. reported revenues of $50.7 million for the second quarter of 2001, a slight increase from $50.1 million in the prior year period. For the first six months of 2001, total revenues reached $108.5 million, up from $97.8 million in the same period of 2000. Product sales, primarily driven by AmBisome®, showed an increase of 9% in the second quarter and 17% for the first half of the year, though foreign currency fluctuations impacted reported growth. Significant increases in Research and Development (R&D) expenses were noted, driven by late-stage clinical programs for Viread™ (tenofovir disoproxil fumarate) and adefovir dipivoxil. This investment is geared towards the anticipated commercial launch of Viread. Despite revenue growth, the company continues to experience substantial net losses, with a net loss of $32.4 million in Q2 2001 and $54.1 million for the first six months, compared to losses of $4.0 million and $21.0 million in the respective prior year periods. The company ended the quarter with $46.9 million in cash and cash equivalents.

Key Highlights

1Total revenues grew slightly to $50.7 million in Q2 2001 and increased by 11% to $108.5 million in the first six months of 2001 compared to the prior year periods.
2Product sales increased by 9% in Q2 2001 and 17% in the first six months of 2001, primarily driven by AmBisome®, with reported growth impacted by foreign currency fluctuations.
3Research and Development (R&D) expenses surged by 61% in Q2 2001 and 77% in the first six months of 2001, reflecting significant investment in late-stage clinical trials for Viread™ and adefovir dipivoxil.
4The company incurred substantial net losses, with a loss of $32.4 million in Q2 2001 and $54.1 million for the first six months of 2001, an increase from prior year periods.
5Cash and cash equivalents significantly decreased by $150.4 million in the first six months of 2001, ending the period at $46.9 million, primarily due to funding operating and investing activities.
6Gilead adopted SFAS 133 for accounting of derivative instruments and hedging activities, which had a minor impact on earnings and equity.
7The company's significant investment in R&D is in preparation for the anticipated commercial launch of Viread™.

GILEAD SCIENCES, INC. Quarterly Report for Q2 Ended Jun 30, 2001

Summary

Key Highlights

Frequently Asked Questions